TG Therapeutics (TGTX) Q1 2026 Earnings
TG Therapeutics reported Q1 2026 revenue of $204.9M (+69.6% YoY), beat analyst consensus of $200.3M by $4.6M. Diluted EPS came in at $0.17 (+466.7% YoY), missed the $0.23 consensus by $0.06.
Financial Snapshot
Trailing eight quarters through Q1 2026
Q1 2026 Earnings FAQ
Common questions about TG Therapeutics's Q1 2026 earnings report.
TG Therapeutics (TGTX) reported Q1 2026 earnings on May 6, 2026 before market open.
TG Therapeutics reported revenue of $204.9M and diluted EPS of $0.17 for Q1 2026.
Revenue beat the consensus estimate of $200.3M by $4.6M. EPS missed the consensus estimate of $0.23 by $0.06.
Compared to the same quarter a year prior, revenue grew 69.6% from $120.9M a year earlier and diluted EPS grew 466.7% from $0.03.
You can read the 8-K earnings release (0001437749-26-015013) and the 10-Q periodic report (0001437749-26-015246) directly on SEC EDGAR. The filing index links above go to sec.gov.